AU2016274655B2 - HPV vaccines - Google Patents

HPV vaccines Download PDF

Info

Publication number
AU2016274655B2
AU2016274655B2 AU2016274655A AU2016274655A AU2016274655B2 AU 2016274655 B2 AU2016274655 B2 AU 2016274655B2 AU 2016274655 A AU2016274655 A AU 2016274655A AU 2016274655 A AU2016274655 A AU 2016274655A AU 2016274655 B2 AU2016274655 B2 AU 2016274655B2
Authority
AU
Australia
Prior art keywords
arenavirus
viral vector
tri
protein
orf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016274655A
Other languages
English (en)
Other versions
AU2016274655A1 (en
Inventor
Andreas ASPÖCK
Ursula BERKA
Katherine Cohen
Gerhard Fuhrmann
Julia HINTERAMSKOGLER
Bettina KIEFMANN
Anders Lilja
Thomas Monath
Klaus Orlinger
Sarah Schmidt
Michael Schwendinger
Elizabeth WATSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hookipa Biotech GmbH
Original Assignee
Hookipa Biotech GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hookipa Biotech GmbH filed Critical Hookipa Biotech GmbH
Publication of AU2016274655A1 publication Critical patent/AU2016274655A1/en
Assigned to HOOKIPA BIOTECH GMBH reassignment HOOKIPA BIOTECH GMBH Alteration of Name(s) of Applicant(s) under S113 Assignors: HOOKIPA BIOTECH AG
Application granted granted Critical
Publication of AU2016274655B2 publication Critical patent/AU2016274655B2/en
Priority to AU2021232660A priority Critical patent/AU2021232660B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10051—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2016274655A 2015-06-10 2016-06-09 HPV vaccines Active AU2016274655B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021232660A AU2021232660B2 (en) 2015-06-10 2021-09-13 HPV vaccines

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562173805P 2015-06-10 2015-06-10
US62/173,805 2015-06-10
US201562254410P 2015-11-12 2015-11-12
US62/254,410 2015-11-12
US201662331158P 2016-05-03 2016-05-03
US62/331,158 2016-05-03
PCT/EP2016/063182 WO2016198531A2 (en) 2015-06-10 2016-06-09 Hpv vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021232660A Division AU2021232660B2 (en) 2015-06-10 2021-09-13 HPV vaccines

Publications (2)

Publication Number Publication Date
AU2016274655A1 AU2016274655A1 (en) 2017-12-21
AU2016274655B2 true AU2016274655B2 (en) 2021-06-17

Family

ID=56137292

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016274655A Active AU2016274655B2 (en) 2015-06-10 2016-06-09 HPV vaccines
AU2021232660A Active AU2021232660B2 (en) 2015-06-10 2021-09-13 HPV vaccines

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021232660A Active AU2021232660B2 (en) 2015-06-10 2021-09-13 HPV vaccines

Country Status (8)

Country Link
US (3) US10669315B2 (cg-RX-API-DMAC7.html)
EP (1) EP3307308A2 (cg-RX-API-DMAC7.html)
JP (2) JP7098330B2 (cg-RX-API-DMAC7.html)
CN (2) CN115197965A (cg-RX-API-DMAC7.html)
AU (2) AU2016274655B2 (cg-RX-API-DMAC7.html)
CA (1) CA2987155A1 (cg-RX-API-DMAC7.html)
HK (1) HK1246183A1 (cg-RX-API-DMAC7.html)
WO (1) WO2016198531A2 (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2604695T1 (sl) 2007-12-27 2023-03-31 Universitaet Zuerich Prorektorat Forschung Replikacijsko defektni arenavirusni vektorji
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
ES2868427T3 (es) 2013-12-03 2021-10-21 Hookipa Biotech Ag Vacunas contra el CMV
CA2967720C (en) 2014-11-13 2024-01-02 Universite De Geneve Tri-segmented arenaviruses as vaccine vectors
EP3307308A2 (en) 2015-06-10 2018-04-18 Hookipa Biotech AG Hpv vaccines
EP3364982A4 (en) * 2015-10-22 2019-04-17 ModernaTX, Inc. VACCINES AGAINST SEXUALLY TRANSMITTED DISEASES
HRP20221474T1 (hr) 2015-11-04 2023-01-06 Hookipa Biotech Gmbh Cjepiva protiv virusa hepatitisa b
SI3373959T1 (sl) 2015-11-12 2022-11-30 Hookipa Biotech Gmbh Arenavirusni delci kot cepiva proti raku
BE1024774B1 (fr) 2016-09-29 2018-07-02 Glaxosmithkline Biologicals Sa Compositions et procedes de traitement
US20200206334A1 (en) * 2016-11-04 2020-07-02 Hookipa Biotech Gmbh Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
AU2018247958A1 (en) * 2017-04-07 2019-10-10 Hookipa Biotech Gmbh Arenavirus particles to treat solid tumors
US20200224220A1 (en) * 2017-07-14 2020-07-16 Oncorus, Inc. Encapsulated polynucleotides and methods of use
EP3461497A1 (en) * 2017-09-27 2019-04-03 GlaxoSmithKline Biologicals S.A. Viral antigens
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
KR102222582B1 (ko) * 2018-02-02 2021-03-04 주식회사 에스엘백시젠 신규 다가 hpv 백신 조성물
CN108424925A (zh) * 2018-03-07 2018-08-21 江苏润洁生物科技有限公司 一种治疗性hpv核酸疫苗
CA3117924A1 (en) * 2018-11-13 2020-05-22 Oncorus, Inc. Encapsulated polynucleotides and methods of use
EP3886886A4 (en) * 2018-11-28 2022-08-24 The General Hospital Corporation T cell-directed anti-cancer vaccines against commensal viruses
JP7125760B2 (ja) * 2019-06-14 2022-08-25 国立研究開発法人理化学研究所 免疫系を賦活化する細胞および当該細胞を含む医薬組成物
AU2020297011A1 (en) * 2019-06-18 2022-02-10 Janssen Sciences Ireland Unlimited Company Arenavirus vectors for hepatitis B virus (HBV) vaccines and uses thereof
WO2021089853A1 (en) * 2019-11-07 2021-05-14 Universität Basel Arenaviruses as vectors
IL292989A (en) * 2019-11-15 2022-07-01 Daiichi Sankyo Co Ltd Nucleic acid lipid particle vaccine enveloping human papillomavirus mrna
KR20230011335A (ko) 2020-05-14 2023-01-20 이노비오 파마수티컬즈, 인크. 재발성 호흡기 유두종증에 대한 백신 및 이의 사용 방법
EP4157342A1 (en) * 2020-05-29 2023-04-05 Hookipa Biotech GmbH Cancer treatment strategies using arenavirus vectors
JP2024512566A (ja) 2021-03-23 2024-03-19 ホオキパ バイオテック ジーエムビーエイチ 前立腺癌の治療に使用されるアレナウイルス
CN115820696A (zh) * 2022-07-28 2023-03-21 怡道生物科技(苏州)有限公司 治疗性多价HPV mRNA疫苗及其制备方法
WO2025056782A1 (en) 2023-09-15 2025-03-20 Hookipa Biotech Gmbh Arenavirus formulations, methods and uses thereof
WO2025155938A1 (en) * 2024-01-18 2025-07-24 Aov Biopharma, Inc. Vaccine for prevention and treatment of human papilloma virus related cancer
WO2025191169A1 (en) * 2024-03-15 2025-09-18 Hookipa Biotech Gmbh Modified arenavirus particles expressing cancer testis antigens as cancer immunotherapies
CN118599010B (zh) * 2024-05-03 2025-06-27 武汉凯德基诺生物技术有限公司 一种hpv16/18/52治疗性疫苗、制备方法和应用
CN118344491B (zh) * 2024-05-03 2025-02-14 华中科技大学同济医学院附属同济医院 一种hpv16/18治疗性疫苗、制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070275003A1 (en) * 2002-10-03 2007-11-29 Wyeth Holdings Corporation Human papillomavirus polypeptides and immunogenic compositions
WO2009083210A1 (en) * 2007-12-27 2009-07-09 Universität Zürich Replication-defective arenavirus vectors

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US6869779B1 (en) * 1998-08-27 2005-03-22 Fuso Pharmaceutical Industries, Ltd. Nucleic acid sequence for potentiating the expression of useful gene and method therefor
DE122008000058I1 (de) * 1999-04-06 2009-05-07 Wisconsin Alumni Res Found Rekombinante influenzaviren zur vakzinherstellung und gentherapie
JP2008521434A (ja) * 2004-11-30 2008-06-26 エーラス グローバル ティービー ワクチン ファウンデーション 組換え二重鎖ＲＮＡヌクレオカプシド類（ｒｄｓＲＮｓ）の生成および産生に有用なバクテリア・パッケージング株およびそれらの利用
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
ES2536426T3 (es) 2006-03-23 2015-05-25 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores
CN102002105B (zh) * 2009-09-03 2013-01-23 中国疾病预防控制中心病毒病预防控制所 Hpv 16型e7e6融合蛋白基因、表达载体、方法、细胞和用途
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
US9492526B2 (en) 2012-01-24 2016-11-15 Sanford Health Polynucleotides for treating oncogenic viral polypeptide positive tumors
WO2013151731A1 (en) * 2012-04-02 2013-10-10 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium for induction of cellular immune response
US8999925B2 (en) * 2013-02-26 2015-04-07 The Administrators Of The Tulane Educational Fund Arenavirus inhibiting peptides and uses therefor
US9809801B2 (en) 2013-03-15 2017-11-07 Université De Genève Anti-mycobacterial vaccines
GB201305361D0 (en) 2013-03-25 2013-05-08 Univ Edinburgh Enhanced expression
ES2868427T3 (es) 2013-12-03 2021-10-21 Hookipa Biotech Ag Vacunas contra el CMV
WO2015183895A1 (en) 2014-05-27 2015-12-03 University Of Rochester Novel arenavirus vaccine
US9943585B2 (en) 2014-07-30 2018-04-17 University Of Rochester Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (LAV)
CN107109371A (zh) 2014-09-22 2017-08-29 明尼苏达大学评议会 皮钦德病毒反向遗传学系统及其使用方法
GB201419572D0 (en) 2014-11-03 2014-12-17 Pirbright Inst The Virus
CA2967720C (en) * 2014-11-13 2024-01-02 Universite De Geneve Tri-segmented arenaviruses as vaccine vectors
DE102015207036A1 (de) 2015-04-17 2016-10-20 Karl Sebastian Lang Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften
EP3307308A2 (en) 2015-06-10 2018-04-18 Hookipa Biotech AG Hpv vaccines
ES3021881T3 (en) 2015-10-23 2025-05-27 Pasteur Institut Recombinant mopeia virus and vaccine platform
HRP20221474T1 (hr) 2015-11-04 2023-01-06 Hookipa Biotech Gmbh Cjepiva protiv virusa hepatitisa b
SI3373959T1 (sl) 2015-11-12 2022-11-30 Hookipa Biotech Gmbh Arenavirusni delci kot cepiva proti raku
WO2017190074A1 (en) 2016-04-28 2017-11-02 The University Of Chicago Lymphangiogenesis for therapeutic immunomodulation
KR20240095333A (ko) 2016-05-18 2024-06-25 유니버시타트 바셀 백신 벡터로서 3개의 세그먼트를 가진 피친드 바이러스
US20200206334A1 (en) 2016-11-04 2020-07-02 Hookipa Biotech Gmbh Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
AU2018247958A1 (en) * 2017-04-07 2019-10-10 Hookipa Biotech Gmbh Arenavirus particles to treat solid tumors
AU2020297011A1 (en) * 2019-06-18 2022-02-10 Janssen Sciences Ireland Unlimited Company Arenavirus vectors for hepatitis B virus (HBV) vaccines and uses thereof
WO2021089853A1 (en) 2019-11-07 2021-05-14 Universität Basel Arenaviruses as vectors
EP4157342A1 (en) 2020-05-29 2023-04-05 Hookipa Biotech GmbH Cancer treatment strategies using arenavirus vectors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070275003A1 (en) * 2002-10-03 2007-11-29 Wyeth Holdings Corporation Human papillomavirus polypeptides and immunogenic compositions
WO2009083210A1 (en) * 2007-12-27 2009-07-09 Universität Zürich Replication-defective arenavirus vectors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
C. REMY-ZILLER ET AL, "Immunological Characterization of a Modified Vaccinia Virus Ankara Vector Expressing the Human Papillomavirus 16 E1 Protein", CLINICAL AND VACCINE IMMUNOLOGY, US, (2014), vol. 21, no. 2, pages 147 - 155 *
Emonet et al. Generation of recombinant lymphocytic choriomeningitis viruses with trisegmented genomes stably expressing two additional genes of interest. PNAS, 2009, 106:3473-3478. *
LUKAS FLATZ ET AL, "Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity", NATURE MEDICINE, (2010), vol. 16, no. 3, pages 339 - 345 *

Also Published As

Publication number Publication date
CN107921117A (zh) 2018-04-17
WO2016198531A2 (en) 2016-12-15
CN107921117B (zh) 2022-06-07
US20230086859A1 (en) 2023-03-23
AU2021232660A1 (en) 2021-10-07
JP2022160401A (ja) 2022-10-19
AU2021232660B2 (en) 2025-02-27
WO2016198531A3 (en) 2017-01-19
CA2987155A1 (en) 2016-12-15
HK1246183A1 (zh) 2018-09-07
US20210024584A1 (en) 2021-01-28
US10669315B2 (en) 2020-06-02
US20180179257A1 (en) 2018-06-28
CN115197965A (zh) 2022-10-18
JP2018518172A (ja) 2018-07-12
EP3307308A2 (en) 2018-04-18
AU2016274655A1 (en) 2017-12-21
JP7098330B2 (ja) 2022-07-11
US11407790B2 (en) 2022-08-09

Similar Documents

Publication Publication Date Title
AU2021232660B2 (en) HPV vaccines
AU2014359276B2 (en) CMV vaccines
US11040096B2 (en) Therapeutic HPV16 vaccines
AU2016348675B2 (en) Vaccines against Hepatitis B virus
US10844096B2 (en) Therapeutic HPV18 vaccines
CN110719788A (zh) 治疗实体瘤的沙粒病毒颗粒
US20070166328A1 (en) Genetic immunization against cervical carcinoma
KR102715320B1 (ko) 신형 hpv 치료용 핵산 백신
Bissa et al. A prime/boost strategy using DNA/fowlpox recombinants expressing the genetically attenuated E6 protein as a putative vaccine against HPV-16-associated cancers
CA2457890A1 (en) Vaccine using papillomavirus e proteins delivered by viral vector
HK40082300A (en) Hpv vaccines
HK1263252B (en) Vaccines against hepatitis b virus
HK1263252A1 (en) Vaccines against hepatitis b virus

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: HOOKIPA BIOTECH GMBH

Free format text: FORMER NAME(S): HOOKIPA BIOTECH AG

FGA Letters patent sealed or granted (standard patent)